journal
Journals Hematology/oncology and Stem C...

Hematology/oncology and Stem Cell Therapy

https://read.qxmd.com/read/34425096/impact-of-pre-transplant-induction-therapy-on-outcomes-of-patients-who-undergo-autologous-stem-cell-transplantation-for-mantle-cell-lymphoma-in-first-complete-remission
#1
LETTER
Omar Albanyan, Samer Alkassis, Seongho Kim, Andrew Kin, Asif Alavi, Lois Ayash, Voravit Ratanatharathorn, Dipenkumar Modi, Joseph P Uberti, Abhinav Deol
Mantle cell lymphoma is a rare subtype of non-Hodgkin's lymphoma with poor prognosis and continue to be challenging to treat. The choice of first line induction regimen remains a topic of debate due paucity of clinical trials. We retrospectively evaluated 66 patients diagnosed with mantle cell lymphoma who achieved first complete response after induction chemotherapy followed by autologous stem cell transplant. Treatment groups were divided into low-intensity versus high-intensity regimens. Our data showed the intensity of induction regimen does not impact posttransplant outcomes of mantle cell lymphoma who underwent autologous stem cell transplant in first complete response...
January 17, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36634283/current-practice-of-oral-care-for-hematopoietic-stem-cell-transplant-patients-a-survey-of-the-eastern-mediterranean-blood-and-marrow-transplantation-group
#2
JOURNAL ARTICLE
Hani Mawardi, Nathaniel Treister, Osama Felemban, Waleed Alamoudi, Ghada Algohary, Abdulrahman Alsultan, Nawal Alshehri, Illias Tazi, Marwan Shaheen, Mohamed Alsharani, Salem Alshemmari, Mutlu Arat, Mohamed Amine Bekadja, Murtadha Al-Khabori, Samar Okaily, Natasha Ali, Husam Abujazar, Wasil Jastaniah, Amir Ali Hamidieh, Sharukh Hashmi, Mahmoud Aljurf
INTRODUCTION: The oral cavity is one of the most common sites impacted by hematopoietic stem cell transplantation (HSCT) with acute complications including mucositis, bleeding, salivary gland dysfunction, infection, and taste alteration. These complications may result in significant morbidity and can negatively impact outcomes such as length of stay and overall costs. As such, oral care during HSCT for prevention and management of oral toxicities is a standard component of transplant protocols at all centers...
January 12, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36634282/outcomes-of-patients-with-thrombocytopenia-evaluated-at-hematology-subspecialty-clinics
#3
JOURNAL ARTICLE
Zaid H Abdel Rahman, Kevin C Miller, Hiba Jabbour, Yaser Alkhatib, Vijaya Donthireddy
BACKGROUND: Thrombocytopenia is a frequently encountered laboratory abnormality and a common reason for hematology referrals. Workup for thrombocytopenia is not standardized and frequently does not follow an evidence-based algorithm. We conducted a systematic analysis to evaluate the laboratory testing and outcomes of patients evaluated for thrombocytopenia at hematology clinics in a tertiary referral center between 2013 and 2016. PATIENT AND METHODS: We performed a comprehensive chart review for patients evaluated for thrombocytopenia during the study period...
January 12, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36634281/azacitidine-maintenance-therapy-post-allogeneic-stem-cell-transplantation-in-poor-risk-acute-myeloid-leukemia
#4
JOURNAL ARTICLE
Amany R Keruakous, Jennifer Holter-Chakrabarty, Sarah A Schmidt, Mohamad O Khawandanah, George Selby, Carrie Yuen
OBJECTIVE/BACKGROUND: Allogeneic hematopoietic stem cell transplant (HSCT) is the potential curative modality for poor-risk acute myeloid leukemia (AML), relapse remains the main reason for transplant failure. Early-phase studies showed azacitidine is safe for post-transplant maintenance therapy in AML. METHODS: We performed a single institutional prospective cohort study to evaluate the benefit of azacitidine maintenance therapy following allogeneic HSCT in poor-risk AML...
January 12, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36634280/prophylactic-pretransplant-ganciclovir-to-reduce-cytomegalovirus-infection-after-hematopoietic-stem-cell-transplantation
#5
JOURNAL ARTICLE
Daniel R Reed, Gina R Petroni, Melissa West, Caroline Jones, Abeer Alfaraj, Paige G Williams, Kathlene DeGregory, Kyle Grose, Sandra Monson, Indumathy Varadarajan, Leonid Volodin, Gerald R Donowitz, Tamila L Kindwall-Keller, Karen K Ballen
OBJECTIVE/BACKGROUND: Cytomegalovirus (CMV) reactivation remains a serious complication after allogeneic hematopoietic cell transplantation (HCT) occurring in approximately 60-70% of CMV-seropositive HCT recipients. CMV reactivation leads to adverse outcomes including end-organ damage, graft-versus-host disease, and graft failure. METHODS: Ganciclovir was administered pretransplant at 5 mg/kg twice daily intravenously from the start of conditioning to Day T-2 to CMV-seropositive patients receiving their first allogeneic HCT...
January 12, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36634279/clinical-utility-of-neutrophil-to-lymphocyte-ratio-in-sickle-cell-disease-with-vaso-occlusive-crisis
#6
JOURNAL ARTICLE
Satish Maharaj, Simone Chang
BACKGROUND AND OBJECTIVES: The neutrophil-to-lymphocyte ratio represents a universally accessible value that correlates with inflammation and prognosis in several disease states; however, the role of this biomarker in sickle cell disease remains poorly explored. Hence, the objective of the present study was to determine its potential clinical utility in patients with sickle cell disease. PATIENTS: Herein, we retrospectively reviewed 143 patients with sickle cell disease who presented to the emergency department with fever and painful vaso-occlusive crisis...
January 12, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36634278/outcome-of-myeloma-patients-with-covid-19-on-active-lenalidomide-based-therapy-does-lenalidomide-protect-from-severe-covid-19
#7
LETTER
Imran K Tailor, Nawal F Alshehry, Syed Z Zaidi, Mohammed A Marei, Ibraheem H Motabi, Mansour Alfayez, Syed Y Altaf
No abstract text is available yet for this article.
January 12, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36634277/radiotherapy-and-immunotherapy-in-melanoma-brain-metastases
#8
REVIEW
Amir Anvari, Pegah Sasanpour, Mania Rajabzadeh Kheradmardi
BACKGROUND AND OBJECTIVE: Melanoma brain metastasis (MBM) generally portends a dismal prognosis. Simultaneous use of radiotherapy (RT) and immune checkpoint inhibitor (ICI) therapy demonstrated tremendous promise and emerged as the new standard. This meta-analysis was conducted to evaluate survival outcomes and toxicities of this combination in patients with MBM. Data analyses were performed using Comprehensive Meta-Analysis software (version 2) and IBM SPSS software (version 27). METHODS: A systematic literature search of PubMed, EMBASE, and the Cochrane Library (via Wiley) was conducted using PICOS/PRISMA selection protocol and included studies to evaluate survival and safety-associated outcomes of ICI + RT for the treatment of MBM...
January 12, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36634276/strange-bedfellows-npm1-mutations-in-acute-promyelocytic-leukemia
#9
JOURNAL ARTICLE
Stephen E Langabeer
No abstract text is available yet for this article.
January 12, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36634275/therapeutic-roles-of-antibody-drug-conjugates-adcs-in-relapsed-refractory-lymphomas
#10
REVIEW
Hamza Hashmi, Alicia Darwin, Taiga Nishihori
Relapsed or refractory lymphoma is commonly treated with combination chemoimmunotherapy and cellular immunotherapy. Modest response rates and associated toxicities are obstacles to achieving durable remission using traditional cytotoxic chemotherapy, especially in frail patients with advanced disease. Antibody drug conjugates represent a new class of novel targeted agents with significant improvement in therapeutic efficacy in the treatment of lymphomas. Several of these agents, which offer improved targeting, greater potency, and better therapeutic index over traditional chemotherapy, are changing the treatment landscape for lymphomas and other hematological malignancies...
January 12, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36634274/use-of-checkpoint-inhibitors-in-gray-zone-lymphoma
#11
JOURNAL ARTICLE
Yensy Mariana Zelaya Rosales, Juliene Lima Mesquita, Yhasmine Delles Oliveira Garcia, Fernando Ricardo Fernandes Paz, Naiana Castelo Branco Campos, João Paulo de Vasconcelos Leitão, Francisco Dário Rocha Filho, Ricardo Vale Albino Oliveira Filho, Romélia Pinheiro Gonçalves Lemes, Fernando Barroso Duarte
Checkpoint inhibitors, cancer immunotherapies, are the new forms of treatment for gray zone lymphoma, a rare subtype that combines the characteristics of both Hodgkin and non-Hodgkin disease forms. Programmed cell death protein 1/programmed cell death ligand 1 (PD-L1/PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) modulate the immune system function. Immunological checkpoints can be stimulatory or inhibitory, and tumors can use these checkpoints to protect against immune system attacks. This is a case report of a difficult diagnosis and describes the most current treatment using checkpoint inhibitors, through the review of the clinical record of a patient diagnosed with gray area lymphoma in August 2019, using a descriptive and cross-sectional analysis of the clinical history and disease evolution...
January 12, 2023: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/34352199/the-impact-of-post-hematopoietic-stem-cell-transplant-tyrosine-kinase-inhibitors-in-philadelphia-positive-acute-lymphoblastic-leukemia
#12
LETTER
Khalid Halahleh, Dalia Al Rimawi, Amal Abu Ghosh, Isra Muradi, Waleed Da'na, Mehdi Hamadani
No abstract text is available yet for this article.
December 23, 2022: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/34118210/primary-mediastinal-large-b-cell-lymphoma-impact-of-chemotherapy-choice
#13
JOURNAL ARTICLE
Rehab Elhagracy, Abdulaziz Hamadah, Rasha Abd El Tawab, Karen Pinto, Amany Hussain, Mohammad Osmani, Salem Alshemmari
OBJECTIVE/BACKGROUND: Data generated from retrospective studies on primary mediastinal B-cell lymphoma (PMBCL) outcome are valuable as no prospective phase 3 trials have been conducted in this rare type of lymphoma. METHODS: Our goal was to assess the long-term outcome of 41 patients with PMBCL who were treated at the Kuwait Cancer Center. We evaluated two types of multidrug treatment, R-CHOP (rituximab, vincristine, doxorubicin, cyclophosphamide, and prednisone) and DA-EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab), and determined overall survival and complete response (CR) as primary endpoints...
December 23, 2022: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36537911/allogeneic-chimeric-antigen-receptor-t-cells-for-hematologic-malignancies
#14
REVIEW
Yang Yang, Xia Bi, Mia Gergis, Dongni Yi, Jingmei Hsu, Usama Gergis
Autologous chimeric antigen receptor (CAR) T cell therapy has been extensively studied over the past decades. Currently, autologous CAR T products are FDA-approved to treat B cell acute lymphoblastic leukemia (B-ALL), large B cell, mantle cell, and follicular lymphomas, and multiple myeloma. However, this therapy has drawbacks including higher cost, production lead time, logistical complexity, and higher risk of manufacturing failure. Alternatively, allogeneic CAR T cell therapy, currently under clinical trial, has inherent disadvantages, including cell rejection, graft versus host disease, and undetermined safety and efficacy profiles...
December 15, 2022: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36537910/chimeric-antigen-receptor-t-cell-therapy-for-solid-tumors
#15
REVIEW
Jingmei Hsu, Yang Yang, Mia Gergis, Xia Bi, Dongni Yi, Usama Gergis
Chimeric antigen receptor T (CAR T) cell therapy has revolutionized the management of lymphoid malignancies. However, it is still in its early phase and is facing many obstacles in solid tumors. Therapeutic challenges in solid tumor lead to tumor target diversification and drive new innovations for the improvement of clinical efficacy. This review showcases early clinical works and sheds light on the most notable successes, drawbacks, and strategies employed to allow CAR T therapy to go full speed ahead.
December 15, 2022: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36537909/chimeric-antigen-receptor-t-cell-therapy-for-acute-myeloid-leukemia
#16
JOURNAL ARTICLE
Xia Bi, Jingmei Hsu, Mia Gergis, Yang Yang, Dongni Yi, Usama Gergis
Chimeric antigen receptor (CAR) T-cells targeting CD19 have drastically improved the outcomes of B-cell malignancies; however, the success has not yet extended to myeloid malignancies such as acute myeloid leukemia (AML). Main impediments in the development of CAR T therapy in AML include difficulty in identifying appropriate target antigens that are specific to myeloid leukemia stem cells while sparing the healthy hematopoietic stem progenitor cells (HSPCs). Herein, we discuss the current state of CAR T-cell therapy in AML, highlighting recent progress and limitations in clinical translation...
December 15, 2022: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36537908/chimeric-antigen-receptor-t-cell-therapies-in-lymphoma-patients-with-central-nervous-system-involvement
#17
REVIEW
Dongni Yi, Mia Gergis, Ghada Elgohary, Jingmei Hsu, Yang Yang, Xia Bi, Usama Gergis
BACKGROUND AND OBJECTIVE: CAR T-cell therapy has significantly improved the outcomes of patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). However, most clinical trials excluded patients with central nervous system (CNS) involvement due to uncertain efficacy and safety. MATERIAL AND METHODS: On January 1, 2022, we searched PubMed to identify all published literature associated with current commercial CAR T-cell therapies for B-NHL, including tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), and lisocabtagene maraleucel (liso-cel)...
December 15, 2022: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36537907/adoptive-cellular-therapy-in-acute-myeloid-leukemia-current-scope-and-challenges
#18
REVIEW
Sankalp Arora, Palash Asawa, Aravind Ramakrishnan, Carlos Bachier, Navneet S Majhail
Adoptive cellular therapies have revolutionized the management of hematologic malignancies, particularly lymphoma and multiple myeloma. These therapies targeting disease-specific antigens, such as CD19 in lymphoma and B cell maturation antigen in multiple myeloma, are efficacious and well-tolerated compared with conventional chemotherapies. Unfortunately, their potential remains unrealized in acute myeloid leukemia (AML). This is because most targetable antigens on AML cells are also expressed on healthy myeloid hematopoietic stem cells (HSC)...
December 15, 2022: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36537906/car-t-cell-therapies-for-b-cell-lymphoid-malignancies-identifying-targets-beyond-cd19
#19
REVIEW
Yenny M Vanegas, Razan Mohty, Martha E Gadd, Yan Luo, Mahmoud Aljurf, Hong Qin, Mohamed A Kharfan-Dabaja
Chimeric antigen receptors (CARs) are synthetic engineered receptors with an antigen recognition domain derived from a high-specificity monoclonal antibody that can target surface molecules on tumor cells. T cells are genetically engineered to express CARs, thereby harnessing the antigen-recognition ability of antibodies and effector function of T cells. Target surface molecule selection is crucial for manufacturing CARs. Ideally, a target surface molecule should be restricted to tumor cells and minimally expressed or absent on normal tissues...
December 15, 2022: Hematology/oncology and Stem Cell Therapy
https://read.qxmd.com/read/36537905/next-generation-chimeric-antigen-receptor-t-cells
#20
REVIEW
Dongni Yi, Mia Gergis, Jingmei Hsu, Yang Yang, Xia Bi, Mahmoud Aljurf, Usama Gergis
The U.S. Food and Drug Administration (FDA) approved 6 CAR T cell (CAR-T) products, including tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), lisocabtagene maraleucel (liso-cel), idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel) in the last 5 years. CAR T-cell therapy significantly improved outcomes for patients with B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). However, recurrence and progression may occur after the initial response due to multiple mechanisms (Zeng and Zhang, 2022) [1]...
December 15, 2022: Hematology/oncology and Stem Cell Therapy
journal
journal
41905
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.